Mild Cognitive ImpairmentMeDi-SUPOLNCT06705738
The Effect of Combination of Mediterranean Diet and Oleocanthal in Patients With Mild Cognitive Impairment
A study testing SUPOL and Dietary Pattern: MeDi in people with Mild Cognitive Impairment, run by Aristotle University Of Thessaloniki at 2 sites in Greece.
Trial summary
BACKGROUND: Mild cognitive impairment (MCI) constitutes a form of preclinical dementia and characterizes a cognitive decline that exceeds what is expected for one's age and education status, but at the same time does not fulfill the criteria for dementia. Read more about this study
- Who is it for?
- Ages 60 to 85 years
- Conditions the study is for
- Mild Cognitive Impairment
- What is being tested?
- SUPOL and Dietary Pattern: MeDi
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 2 sitesGreece
- Study dates
- 31 Jan 2025to 30 Nov 2029
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants are eligible to be included in this study only if all the following criteria apply:
- Men or women,
- 60 to 85 years of age inclusive, at the time of signing the informed consent form (ICF).
- Mini-Mental State Examination (MMSE) score of 26-28 at Screening (Visit 1).
- Montreal Cognitive Assessment (MoCA) score of 20-26 at Visit 1.
- MRI scan evaluation at Visit 1.
Show all 10Show fewer
- CSF biomarkers evaluation at Visit 1.
- Adequate knowledge and understanding of the Greek language, as well as adequate literacy, vision and hearing for neuropsychological testing in the opinion of the Principal Investigator (PI) at the time of screening.
- They are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Who cannot join
- Participants are excluded from the study if any of the following criteria apply:
- Medical conditions
- Significant neurological diseases that affect the central nervous system other than MCI, that may affect cognition ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease (PD), Multiple sclerosis (MS), multiple concussions, epilepsy or recurrent seizures.
- Ongoing serious or unstable illnesses, including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, psychiatric, immunologic, hema-tologic diseases and other conditions that, in the PI's opinion, could interfere with the analyses in this study or has a life expectancy of less than 24 months.
- History of cancer within the last 5 years, with exception of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, other cancers with low risk of recurrence or spread.
- Participants with any current primary psychiatric diagnosis, if in the judgement of the PI for the psychiatric disorder or symptom is likely to confound interpretation of the combined approach effect, affect cognitive assessment or affect the partici-pant's ability to complete the study. Participants with history of schizophrenia or other chronic psychosis are excluded.
Show all 32Show fewer
- In the judgement of the PI, participants are actively suicidal and therefore deemed to be at significant risk of suicide.
- History of alcohol or drug abuse disorder (except tobacco use disorder) within 2 years before Visit 1.
- History of clinically significant multiple or severe drug allergies, significant atopy or severe post-treatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis and/or exfoliative dermatitis).
- Patient has undergone surgical operation of the gastrointestinal tract (GI tract) that led to removal of a functional part of the GI tract, length shortage of the GI tract and change of the GI tract morphology.
- Imaging, Vital Signs, Laboratory Tests and Physical Examinations
- Any clinically important abnormality at Visit 1, as determined by the PI, in physical or neurological examination, vital signs or clinical laboratory test results, that could be detrimental to the participant, could compromise the study or show evidence of other etiologies for MCI.
- MRI which shows evidence of significant abnormality that would suggest another potential etiology for MCI or a clinically significant finding that may impact the participant's ability to safely participate in the study.
- Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.
- Poor venous access.
- Evidence of a relevant neurological disorder other than MCI at Visit 1, including but not limited to PD, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, MS, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV, learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits.
- Evidence of a clinically relevant or unstable psychiatric disorder, based on Diag-nostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or in the case that depression is controlled with treatment can be included in the trial per inves-tigator's judgement.
- Imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicide Severity Rating Scale (C-SSRS) or of harm to self or others in the opinion of the PI.
- Prior or Concomitant Therapy
- Known allergies to EVOO, OLC, Oleacein (OLE), Oleuropein Aglycon (OLA), Ligstroside Aglycon (LIG), Tyrosol (TYR), Hydroxytyrosol (HT) or any other components of the formulation.
- Contraindications in following a MeDi or Western diet pattern and are not willing to adhere to the abovementioned nutritional lifestyles.
- Consumption of high-dose nutritional supplements.
- Long-term antibiotic therapy.
- Regular consumption of probiotics.
- Regular intake of enriched commercial probiotic foods.
- Prior or Concurrent Clinical Study Experience
- Currently enrolled in any other interventional clinical trial involving an investigational medicinal product (IMP) or any other type of medical research judged not to be scientifically or medically compatible with this study.
- Participated, within the last 30 days in a clinical trial involving an IMP. If the precious IMP is scientifically or medically incompatible with this study and has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed prior to Visit 1 (participation in observational studies may be permitted upon review or the observational study protocol and approved by the PI).
- Previously completed or withdrawn from this study or received SUPOL in any prior investigational study. (This exclusion criterion does not apply to participants who are allowed to rescreen before randomization in this study).
- Other exclusions
- Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
- Currently OMPHAX SA (OMPHAX) employees or employees of third-party organizations (TPOs) involved in study which requires exclusion of their employees or have relatives or partners who are OMPHAX employees or are employees of TPOs involved in a study which requires exclusion of their employees.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Greece2 sites, 2 recruiting
- Not yet recruiting
"AHEPA" General University Hospital of Thessaloniki
Thessaloniki, Thessaloniki, 54636
Thomas Tegos, Associate Professor, 0030 2310994780, thomtegos@gmail.com
- Recruiting
Greek Association of Alzheimer's Disease and Related Disorders
Thessaloniki, Thessaloniki, 54643
Magdalini Tsolaki, Emeritus Professor, 0030 2310 2411 56, tsolakim1@gmail.com
About this study
BACKGROUND: Mild cognitive impairment (MCI) constitutes a form of preclinical dementia and characterizes a cognitive decline that exceeds what is expected for one's age and education status, but at the same time does not fulfill the criteria for dementia. MCI is considered a prodromal stage of Alzheimer's disease (AD) and the progression to this neurodegenerative disease, renders the patients heavily dependent on their relatives and the society, which creates a huge psychological and financial burden, since no effective treatment exists for MCI and AD to this day. Mediterranean diet (MeDi) displays beneficial effects on the cognitive function of both healthy individuals and cognitive impaired patients. High Phenolic Early Harvest Extra Virgin Olive Oil (HP-EH-EVOO) is a natural product that contains high concentrations of the substance Oleocanthal (OLC), while at the same time it has been shown to exert beneficial properties on the cognitive function of cognitive impaired individuals, as well as on the slowing down of the decline of cognitive function.
AIM: The main hypothesis that will be evaluated is whether the combined approach of the MeDi pattern and the concurrent intervention with the administration in a capsule form of the supplement containing olive oil polyphenols with the main substance being Oleocanthal (SUPOL), could constitute a considerable strategy of management of MCI patients.
Study Type: Investigational Study Design, Allocantion: Randomized Intervention Model, Parallel Assignment Masking: Double Blind (Subject, Outcome Assessor - Investigator) on Supplement, Primary Purpose: Prevention.
Read the detailed description
OBJECTIVE OF THE TRIAL: To evaluate the efficacy of the combined approach of the MeDi pattern and the concurrent SUPOL compared to the MeDi diet pattern in combination with placebo on the change in cognition and function in subjects with MCI.
STUDY DESIGN: The study is designed as a 2x2 quasi-factorial design, which combines the characteristics of a prospective cohort study regarding dietary patterns and a randomized, placebo-controlled, 4-parallel-group clinical trial, double-blinded with respect to the dietary supplement.
PARTICIPANTS: Participants upon enrollment will be classified into two distinct cohorts based on their level of adherence to the MeDi (high and moderate adherence). The recruitment of N=200 participants with MCI is planned, who will initially be stratified into two strata: high adherence to the MeDi (n=100) and moderate adherence to the MeDi (n=100). Subsequently, participants within each cohort will be randomized in a 1:1 ratio to receive either SUPOL or placebo, creating 4 groups of n=50 individuals:
- Group 1: High adherence to the MeDi and SUPOL intake
- Group 2: High adherence to the MeDi and placebo intake
- Group 3: Moderate adherence to the MeDi and SUPOL intake
- Group 4: Moderate adherence to the MeDi and placebo intake.
The assessment and grading of participants' adherence to the MeDi at baseline will be performed using the MedDietScore. Participants will be classified as follows:
- Moderate adherence to the MeDi: MedDietScore 21-35
- High adherence to the MeDi: MedDietScore 36-55
- Patients with low adherence to the MeDi (MedDietScore 0-20) will be excluded from the study to ensure the homogeneity of the comparison groups.
DURATION: The duration of the intervention will be 12 months, while the neuropsychological assessment and laboratory testing will be performed at baseline, after the end of the intervention at 12 months and at 18 months (6 months after the completion of the intervention). The total study duration will be 18 months.
LOCATION: The study will be conducted in Thessaloniki and will recruit patients having diagnosed with MCI from the outpatient clinic 1st Neurological Clinic of the General University Hospital "AHEPA" (AHEPA) and the Greek Association of Alzheimer's Disease and Related Disorders (Alzheimer Hellas).
SCREENING - RANDOMIZATION - BASELINE (Visit 1): Patient eligibility will be determined during Visit 1. A protocol eligibility form will be completed for each patient and reviewed by the Principal Investigator (PI) approval prior to participation in the study. If eligibility is reached, baseline assessments, as well as randomization for group allocation will take place.
- Conditions
- Mild Cognitive Impairment
- Being tested
- SUPOL, Dietary Pattern: MeDi
- Keywords
- Mediterranean diet, Western type diet, Olive oil polyphenols, Oleocanthal, Mild cognitive impairment, Alzheimer disease
- Medical subject headings
- Cognitive Dysfunction, Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SUPOLDietary supplement
Supplement containing Olive Oil Polyphenol with the main substance being Oleocanthal (SUPOL), 2 capsules twice a day (4 capsules total) for 12 months.
Dietary Pattern: MeDiOther
High Adherance to MeDi pattern to be followed for 12 months.
| Study group | Role | What they receive |
|---|---|---|
| 1st group | Experimental | 50 participants with high adherence to the MeDi pattern will receive SUPOL for 12 months. Receives: Dietary Supplement: SUPOL; Other: Dietary Pattern: MeDi |
| 2nd group | Placebo comparator | 50 participants with high adherence to the MeDi pattern will receive placebo for 12 months. Receives: Other: Dietary Pattern: MeDi |
| 3rd group | Active comparator | 50 participants with medium adherence to the MeDi pattern will receive SUPOL for 12 months. Receives: Dietary Supplement: SUPOL |
| 4th group | No intervention | 50 participants with medium adherence to the MeDi pattern will receive placebo for 12 months. |
What is being measured
The primary outcome is the main question the study is designed to answer.
ADAS-Cog - Measurement to Assess the Severity of Cognitive Impairment
Alzheimer's Disease Assessment Scale - Cognitive Subscale - 13 (ADAS-Cog-13) neuropsychological assessment scale scores ranges from 0 to 85, with greater scores showing a more significant cognitive impairment
Measured: Baseline (Day 1) to 12 months
MMSE - Measurement to Assess and Evaluate Cogntive Function
Mini-Mental State Examination (MMSE) score ranges range from 0 to 30 and individuals will lower MMSE scores show greater cognitive impairment
Measured: Baseline (Day 1) to 12 months
Secondary outcomes (13)
MoCA - Measurement to Assess Cognitive Abilities
Montreal Cognitive Assessment (MoCA) total score ranges from 0 to 30 and lower scores indicating greater impairment
Measured: Baseline (Day 1) to 12 months
ADCS-ADL-MCI - Measurement to Assess and Evaluate the Performance in Different Activities of Daily Living
Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-ADL-MCI) MCI scale score ranges from 0 to 53, with poorer scores representing a more significant cognitive impairment
Measured: Baseline (Day 1) to 12 months
CDR-SB - Measurement to Assess the Severity of the Disease and the Progression of the Disease
Clinical Dementia Rating Sum of Boxes (CDR-SB) total score ranges from 0 to 18, with greater scores corresponding to more significant impairment
Measured: Baseline (Day 1) to 12 months
CDR - Measurement of Time to Progression to Dementia
Clinical Dementia Rating (CDR) global score ranges from 0 to 3, with the higher score corrisponding to severe dementia and the time to progression to dementia will be measured in weeks (unit)
Measured: Baseline (Day 1) to 12 months
GDS - Measurement to Identify Depression in the Elderly
Geriatric Depression Scale (GDS) total score ranges from 0 to 30, with the classification of severity to be: (a) normal 0-9, (b) mild depression 10-19 and (c) severe depression 20-30
Measured: Baseline (Day 1) to 12 months
C-SSRS - Measurement to Determine the Potential Risk for Suicide
"The Columbia-Suicide Severity Rating Scale (C-SSRS) Intensity of Ideation score ranges from 0 to 25, with higher numbers indicating more intense suicidal ideation
Measured: Baseline (Day 1) to 12 months
TEAEs - Measurment of Number of Treatment Emergent Adverse Events
Number of treatment emergent adverse events (TEAEs) are measured in number of events from baseline
Measured: Baseline (Day 1) to 12 months
Measurement of Change in the Vital Signs
Number of participants with change from baseline in blood pressure (measured in mmHg) will be assessed
Measured: Baseline (Day 1) to 12 months
Measurement of Change in the Vital Signs
Number of participants with change in pulse rate (heart beats per minute) will be assessed
Measured: Baseline (Day 1) to 12 months
Measurement of Change in Physical Examination
Number of participants with change from baseline in physical examination will be evaluated
Measured: Baseline (Day 1) to 12 months
Measurement of Change in Neurological Examination
Number of participants with change from baseline on neurological examination will be evaluated
Measured: Baseline (Day 1) to 12 months
Measurment of Change in Clinical Laboratory Tests
Number of participants with change from baseline in biochemical test will be evaluated
Measured: Baseline (Day 1) to 12 months
Measurement of Change in Clinical Laboratory Tests
Number of participants with change from baseline in haematological test wiil be evaluated
Measured: Baseline (Day 1) to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Nov 2024
- Study start31 Jan 2025
- Primary completion30 Sep 2029 (estimated)
- Study completion30 Nov 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The overall design of the study will be a randomized 4-arm parallel controlled clinical trial, single-blinded for the dietary intervention (MeDi and Western diet) and double-blinded for the intervention (SUPOL and placebo).
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aristotle University Of Thessaloniki
- Sponsor type
- University, hospital or other
- Collaborators
- Greek Alzheimer's Association and Related Disorders, University of Glasgow, World Olive Center for Health, National and Kapodistrian University of Athens
- Responsible party
- Principal investigator, Magda Tsolaki, Aristotle University Of Thessaloniki
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06705738
- Sponsor's protocol ID
- AUTh
- Acronym
- MeDi-SUPOL
- Status last verified
- Oct 2026
- First submitted
- 8 Nov 2024
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No plans to share data with other researchers